
    
      This is a multicenter, randomized, double-blind, placebo-controlled trial in which one group
      will be treated with PG102P (1.5 g/day) and the other with a placebo. It is an
      investigator-initiated clinical trial. A superiority trial is planned to test the hypothesis
      that PG102P is effective in relieving pruritus for patients with ESRD undergoing HD.
    
  